Quanterix Corporation (QTRX) entered a merger agreement on January 10, 2025, to acquire Akoya Biosciences, Inc. (AKYA) in an all-stock deal valued at about $286.34 million, to create the first combined solution for highly sensitive detection of protein biomarkers in blood and tissue.
Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock they own, which is valued at approximately $3.73 per share, representing a premium of 40.23% from the stock’s last close.
Quanterix shareholders will own about 70% of the merged company, while Akoya shareholders will own about 30%.
Akoya Biosciences is a life sciences technology company that provides tools for researchers to study cells in their natural tissue environment, offering spatial biology solutions that help advance discovery and clinical research globally.
Quanterix is a life sciences company that develops advanced tools for detecting tiny amounts of biomarkers—specific molecules in the body linked to diseases—using digital immunoassay platforms. Immunoassays use antibodies to find and measure these biomarkers, which helps improve research and diagnostics in areas like neurology, cancer, and heart disease while advancing precision health.
“This transaction accelerates our progress by creating the first platform that lets researchers and clinicians track disease progression from tissue to blood. By starting with tissue and detecting early signs of complementary proteins in blood using leading ultra-sensitive SIMOA technology, we are uniquely positioned to speed up market development of new liquid biopsy tests,” said Masoud Toloue, the Chief Executive Officer of Quanterix.
The deal is expected to generate about $40 million in annual cost synergies by the end of 2026, with $20 million expected to be achieved within the first year after the deal closes, which is expected in the second quarter of 2025.
Masoud Toloue, the current CEO of Quanterix, will serve as the CEO of the combined company, while Quanterix Chief Financial Officer Vandana Sriram will take over the CFO role of the combined company. The company will retain the Quanterix name.
After the deal is completed, the Quanterix Board will have nine members. Two current directors from Quanterix will step down, and Quanterix will add two directors chosen by Akoya from their current Board.
Perella Weinberg Partners provided financial advisory services to Akoya, while DLA Piper offered legal advisory services. Quanterix, on the other hand, relied on Goldman Sachs for financial guidance and legal counsel from Covington & Burling.
Quanterix is acquiring Akoya at 1.67 times its sales.
For a detailed breakdown of this merger and acquisition transaction, please visit the Deal Metrics page here:
Deal Metrics for the acquisition of Akoya Biosciences, Inc. (AKYA) by Quanterix Corporation (QTRX)
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please conduct your own research before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article